MABS: Targeted therapy tailored to the patient’s need

British Journal of Nursing

Volumn 24, Issue Sup16a, 2015, Pages S4-S13

  El Miedany, Yasser ^a  

^a DARENT VALLEY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ADVERSE EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS; OCCUPATIONAL EXPOSURE; PATIENT CARE; PROCEDURES;

ANTIBODIES, MONOCLONAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OCCUPATIONAL EXPOSURE; PATIENT-CENTERED CARE;

EID: 84964693966     PISSN: 09660461     EISSN: 20522819     Source Type: Journal    
DOI: 10.12968/bjon.2015.24.Sup16a.S4     Document Type: Article

References (47)

1. Acharya S, Shukla S, Mahajan S, Diwan S (2011) The charisma of ‘Magic Bullets’–monoclonal antibodies (mAB/moAB) in clinical medicine. JIACM 12(4): 283–9
2. Alexander M, King J, Bajel A, Doecke C et al (2014) Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel. Intern Med J 44(10): 1018–26. doi: 10.1111/imj.12564
3. Archavlis E, Nievas M (2013) Cerebral vasospasm: a review of current developments in drug therapy and research. J Pharm Technology & Drug Res doi: 10.7243/2050-120X-2-18. http://tinyurl.com/pzh6erm (accessed 6 July 2015)
4. Bach JF (2011) Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 378(9790): 459–60
5. Bharat A, Xie F, Baddley JW, Beukelman T, Chen L et al (2012) Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken) 64(4): 612–5. doi: 10.1002/acr.21564.
6. Breslin S (2007) Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007; 11(1 Suppl):37–42.
7. Breast Cancer Care (2015) Trastuzumab (Herceptin). http://tinyurl.com/nl7ahzy (accessed 6 July 2015)
8. Butzkueven H, Kappos L, Pellegrini F et al (2014) Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 85(11): 1190–7
9. Bybel B, Brunken RC, DiFilippo FP, Neumann DR, Wu G, Cerqueira MD (2008) SPECT/CT imaging: clinical utility of an emerging technology. Radiographics 28(4): 1097–113. doi: 10.1148/rg.284075203.
10. Chandel P, Harikumar S (2013) Pharmaceutical monoclonal antibodies: production, guidelines to cell engineering and applications. Int J Pharm Pharm Sci 5(2): 13–20
11. D’Amico E, Caserta C, Patti F (2015) Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. Expert Rev Neurother 15(3): 251–68. doi: 10.1586/14737175.2015.1008458
12. Dai H, Peng F, Lin M, Xia J et al (2015) Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40/CD40L and LFA-1/ ICAM-1 blockade. Transpl Immunol 32(2): 84–91. doi: 10.1016/j.trim.2015.01.001
13. D’haeseleer M, Beelen R, Fierens Y, Cambron M, Vanbinst AM et al (2013) Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. Proc Natl Acad Sci U S A. 110(14): 5654–8. doi: 10.1073/ pnas.1222560110. Epub 2013 Mar 18.
14. Dubey D, Kieseier B, Hartung H et al (2015) Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Rev Clin Immunol 11(1): 93–108. doi: 10.1586/1744666X.2015.992881. Epub 2014 Dec 15
15. Dziewierz A, Rakowski T, Dudek D (2014) Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives. Ther Clin Risk Manag 10:567–76. doi: 10.2147/TCRM.S50002. eCollection 2014
16. El Miedany Y (2002) The evolving therapy of rheumatic diseases, the future is now. Curr Drug Targets—Immune Endocr Metabol Disord 2(1): 1–11
17. El Miedany Y, Palmer D (2014) Rheumatoid arthritis: recommendations for treat to target. Br J Nurs 23(6): 310–5
18. El Miedany Y, El Gaafary M, Ahmed I et al (2015) US guided treat-to-target approach in early RA: implications for uncoupling of disease activity and structural joint damage. Curr Rheum Rev 11(1): 1–7
19. European Medicines Agency (2005) Public Statement On Cea-Scan (arcitumomab). http://tinyurl.com/olozdn6 (accessed 6 July 2015)
20. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069): 522–5
21. Kawashima H (2014) Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. Scientific World Journal 2014: 492061. doi: 10.1155/2014/492061. Epub 2014 Oct 14.
22. Kantarjian H, Thomas D, Jorgensen J et al (2013) Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukaemia. Cancer 119(15): 2728–36. doi: 10.1002/cncr.28136. Epub 2013 Apr 30
23. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. J Immunol 174(5): 2453–5
24. Kornek B (2015) An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. Patient Prefer Adherence 19(9): 675–84. doi: 10.2147/PPA.S20791
25. Kounis G, Soufras G, Tsigkas G, Hahalis G (2014) Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome. Oncoimmunology 3: e27987
26. Ludwig D, Pereira D, Zhu Z et al (2003) Monoclonal antibody therapeutics and apoptosis. Oncogene 22(56): 9097–106
27. Mari Aparici C, Seo Y (2012) Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med 42(5):328–42. doi: 10.1053/j. semnuclmed.2012.04.004
28. Millard M, Odde S, Neamati N (2011) Integrin targeted therapeutics. Theranostics 1:154–88. doi:10.7150/thno/v01p0154
29. Miller B, Turan N, Chau M, Pradilla G (2014) Inflammation, vasospasm, and brain injury after subarachnoid hemorrhage. Biomed Res Int 2014: 384342. doi: 10.1155/2014/384342. Epub 2014 Jul 3
30. Milstein C, Cuello AC (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305(5934): 537–40
31. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81(21): 6851–5
32. Nanau R, Neuman M (2014) Safety of Anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci 17(3): 324–61
33. National Institute of Health and Care Excellence (NICE) (2004) Immunosuppressive therapy for renal transplantation in adults. www.nice.org.uk/guidance/ta85 (accessed 6 July 2015)
34. National Institute of Health and Care Excellence (NICE) (2015) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262). https://www.nice.org.uk/guidance/ta329 (accessed 19 July 2015)
35. Rini BI (2007) Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 13(4): 1098–106
36. Sabatine MS, Giugliano RP, Wiviott SD (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16): 1500–9. doi: 10.1056/NEJMoa1500858
37. Salsano M, Treglia G (2013) PET imaging using radiolabled antibodies: future direction in tumour diagnosis and correlated applications. Research and Reports In Nuclear Medicine 3: 9–17
38. Savvatis K, Müller I, Fröhlich M et al (2014) Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis. Basic Res Cardiol 109(6): 449. doi: 10.1007/s00395-014-0449-2
39. Siddiqui M (2010) Monoclonal antibodies as diagnostics; an appraisal. Indian J Pharm Sci 72(1): 12–7
40. Silverstein AM (1989) A History of Immunology. Academic Press, New York NY
41. Singh J, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet pii: S0140-6736(14)61704-9. doi: 10.1016/S0140-6736(14)61704-9
42. Stys P (2013) Pathoetiology of multiple sclerosis: are we barking up the wrong tree? F1000Prime Rep 5:20. doi:10.12703/P5-20
43. Tavori H, Giunzioni I, Fazio S (2015) PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9. Curr Opin Endocrinol Diabetes Obes 22(2): 126–32. doi: 10.1097/MED.0000000000000137
44. Tewari K, Sill M, Long H, Penson R et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8): 734–43. doi: 10.1056/NEJMoa1309748
45. US Food and Drug Administration (2001) Guidance for Industry: Monoclonal Antibodies Used as Reagents in Drug Manufacturing. http://tinyurl.com/ond6ldt (accessed 6 July 2015)
46. Vaswani SK, Hamilton RG (1998) Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol 81(2): 105–15
47. Vogel WH (2010) Infusion reactions: diagnosis, assessment and management. Clin J Oncol Nurs 14(2): E10–21. doi: 10.1188/10.CJON.E10-E21.